文献速递前列腺癌

4Kscore、ExosomeDx与多参数磁共振早期检测高级别前列腺癌的临床价值

Clinical Utility of 4Kscore®, ExosomeDx™ and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer.
PubMed 文献 · J Urol · 2020-09-08

研究纳入783例接受液体生物标志物检测(联合或不联合多参数磁共振)的患者,评估4Kscore与ExosomeDx对Gleason分级分组≥2前列腺癌的检测价值及可避免活检数。结果显示以厂家截点限制活检可避免29.5%–39.9%不必要的活检,但漏诊4.0%–4.8%的Gleason≥2癌;先行液体标志物、阳性者再行磁共振、磁共振阳性或4Kscore≥20/ExosomeDx≥19再活检的流程可避免39.4%–43.0%活检和29.5%–39.9%磁共振,漏诊4.8%–5.6%。

要点

  • 液体标志物高于厂家截点与PI-RADS 3–5及Gleason≥2癌相关。
  • 单用液体标志物截点限制活检可避免29.5%–39.9%活检但漏诊4.0%–4.8%。
  • 先液体标志物后磁共振的序贯流程可减少活检与磁共振且漏诊率可控。

核心结论

  • 以液体生物标志物为先、结合多参数磁共振及特定阈值的筛查流程可减少不必要活检、磁共振检查及Gleason 1级癌的过度检出。

研究设计与样本

  • 回顾性队列研究,总体队列783例,其中419例(53.5%)接受活检。
  • 患者接受1次液体生物标志物检测,联合或不联合多参数磁共振。
  • 高级别前列腺癌定义为Gleason分级分组2或以上。

主要发现

  • 4Kscore与ExosomeDx评分高于厂家截点与PI-RADS 3–5及Gleason≥2癌相关。
  • 仅以液体标志物高于厂家截点限制活检可避免29.5%–39.9%不必要的活检,但活检组漏诊4.0%–4.8%的Gleason≥2癌。
  • 先行液体标志物、阳性者行磁共振、磁共振阳性或4Kscore≥20或ExosomeDx≥19再活检的流程,活检组漏诊4.8%–5.6%的Gleason≥2癌,避免39.4%–43.0%活检和29.5%–39.9%磁共振。
  • 先行磁共振、阴性者再行液体标志物的流程活检组漏诊2.4%的Gleason≥2癌,仅避免17.2%–19.3%活检。

关键数值与推荐

  • 活检避免率29.5%–39.9%对应仅用液体标志物厂家截点限制活检的策略。
  • 漏诊4.0%–4.8%的Gleason≥2癌对应仅用液体标志物截点限制活检的活检组。
  • 漏诊4.8%–5.6%的Gleason≥2癌对应先液体标志物后磁共振序贯流程的活检组。
  • 避免39.4%–43.0%活检和29.5%–39.9%磁共振对应先液体标志物后磁共振序贯流程。
  • 4Kscore 20或ExosomeDx 19为序贯流程中决定是否活检的阈值。

临床怎么用

  • 对疑似前列腺癌患者可先检测液体生物标志物,高于厂家截点者再行多参数磁共振。
  • 磁共振阳性或4Kscore≥20或ExosomeDx≥19时进行活检,以减少不必要穿刺。
  • 该序贯策略可同时减少磁共振检查数量及Gleason 1级癌的过度检出。

局限性

  • 原文未报告研究设计类型、随访时长及多中心与否等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to evaluate 4Kscore® and ExosomeDx™ with multiparametric magnetic resonance imaging in the detection of high grade prostate cancer and number of biopsies avoided. MATERIAL AND METHODS: Patients had 1 liquid biomarker test with or without multiparametric magnetic resonance imaging. High grade prostate cancer was defined as Gleason grade group 2 or greater. The overall number of avoided biopsies (with Gleason grade 1 or less), and number of missed Gleason grade 2 or greater cancer among the biopsied patients, were determined. RESULTS: Of the 783 patients in the overall cohort 419 (53.5%) underwent biopsy. 4Kscore and ExosomeDx scores higher than the manufacturers' cut point were associated with PI-RADS™ scores 3 to 5 and Gleason grade 2 or greater prostate cancer. Limiting biopsy to the men with liquid biomarker scores above the manufacturers' cut point would have resulted avoiding 29.5% to 39.9% unnecessary biopsies overall, while missing 4.0% to 4.8% Gleason grade 2 or greater prostate cancer in the biopsy group. Screening algorithms with up-front liquid biomarker testing followed by multiparametric magnetic resonance imaging if the biomarker is above the manufacturers' cut point, then followed by biopsy if the multiparametric magnetic resonance imaging is positive or if 4Kscore 20 or greater or ExosomeDx 19 or greater would have missed 4.8% to 5.6% of Gleason grade 2 or greater prostate cancer in the biopsy group while avoiding 39.4% to 43.0% biopsies and 29.5% to 39.9% multiparametric magnetic resonance imaging overall. Similar algorithms with up-front multiparametric magnetic resonance imaging followed by liquid biomarker testing for negative multiparametric magnetic resonance imaging would have missed 2.4% of Gleason grade 2 or greater prostate cancer in the biopsy group but only avoided 17.2% 19.3% biopsies overall. CONCLUSIONS: Screening algorithms with up-front liquid biomarker testing followed by multiparametric magnetic resonance imaging and biopsy at certain biomarker thresholds could reduce unnecessary biopsies, multiparametric magnetic resonance imaging and overdetection of Gleason grade 1 prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. de la Calle CM, Fasulo V, Cowan JE, et al. Clinical Utility of 4Kscore®, ExosomeDx™ and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer. J Urol. 2020. PMID: 32897802. doi:10.1097/JU.0000000000001361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。